ELITE PHARMACEUTICALS, INC /NV/ — Key Metrics
2 years of history · ending 2025-03-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-0
Book Value Per Share
$0
Free Cash Flow Per Share
$0
Cash Per Share
$0
Revenue Per Share
$0
OCF Per Share
$0
Return on Equity
-7.8%
Return on Assets
-4.8%
Return on Invested Capital
27.9%
Debt to Equity
—
Current Ratio
4.88
Quick Ratio
3.50
Asset Turnover
0.93
Days Sales Outstanding
126.85
Days Payables Outstanding
24.56
Days Inventory On Hand
134.85
Cash Conversion Cycle
237.14
R&D / Revenue
9.5%
SBC / Revenue
—
Capex / Revenue
1.9%
Working Capital
$46M
Net Current Asset Value
$15M
Invested Capital
$54M
OCF / Net Income
-1.73
FCF / Net Income
-1.35
Accruals Ratio (Sloan)
-12.2%
Net Debt
$-7M
Net Debt / EBITDA
-0.59
Interest Coverage
152.85
Cash Coverage
58.14
Capex Coverage
4.59
Tangible Common Equity
$48M
TCE / Total Assets
49.7%
NOPAT
$15M
Cash ROIC
10.5%
WC / Revenue
54.6%
Capex / D&A
1.33
Reinvestment Rate
2.0%
Asset Growth vs Revenue Growth
-33.2%
Revenue 5Y CAGR
36.1%
EPS 5Y CAGR
—
Book Value 5Y CAGR
38.1%
Stock Price (FY-end)
$0
Market Cap
$470M
P/E Ratio
7.63
P/S Ratio
5.59
P/B Ratio
8.78
P/TB Ratio
9.82
P/OCF Ratio
63.05
P/FCF Ratio
80.62
Enterprise Value
$470M
EV / EBITDA
22.57
EV / Sales
5.59
EV / FCF
80.62
FCF Yield
1.2%
R&D Yield
1.7%
Capex Yield
0.3%
Operating Leverage
1.69
Graham Number
$0
Shares Variation (YoY)
4.4%
Beta (5Y)
0.14
Cost of Equity
5.2%
Cost of Debt (after tax)
—
52W High
$1
52W Low
$0
Trailing Return 1Y
193.3%
Trailing Return 5Y
528.6%
F-Score (Piotroski)
5.00
Z-Score (Altman)
6.94
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.